Devdatt Kurdikar - 31 Mar 2026 Form 4 Insider Report for ZIMMER BIOMET HOLDINGS, INC. (ZBH)

Reporting relationship: Director
Issuer ticker: ZBH
Reported as of: 31 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Apr 2026, 16:16:18 UTC
Prior SEC filing: 05 Jan 2026
Next SEC filing: 27 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew R. St. Louis, Attorney-in-Fact for Devdatt Kurdikar (power of attorney previously filed)

Key filing fact

Devdatt Kurdikar filed Form 4 for ZIMMER BIOMET HOLDINGS, INC. (ZBH) on 02 Apr 2026.

Key facts

This page summarizes Devdatt Kurdikar's Form 4 filing for ZIMMER BIOMET HOLDINGS, INC. (ZBH).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Apr 2026, 16:16.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001910621 Primary reporting owner

Kurdikar Devdatt

Relationship: Director
Address: 345 E. MAIN STREET, WARSAW
Signature: /s/ Matthew R. St. Louis, Attorney-in-Fact for Devdatt Kurdikar (power of attorney previously filed)
Signature date: 02 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZBH transaction Derivative

Phantom Stock Units

Award

Transaction value
Shares: +154
Change %: +8.7%
Price: $0.000000^*
Shares after: 1,929
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 154
Exercise price: $89.08
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

Footnote F2

The Conversion or Exercise Price of Derivative Security is 1-for-1.

Footnote F3

Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.

Footnote F4

Includes 4.508 phantom stock units accrued on January 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.